For decades, the medical community has faced a frustrating dilemma: cardiovascular disease remains the leading cause of death worldwide, yet the pipeline for new treatments is a high-risk gamble that usually ends in failure.
For decades, the medical community has faced a frustrating dilemma: cardiovascular disease remains the leading cause of death worldwide, yet the pipeline for new treatments is a high-risk gamble that usually ends in failure.